Published in Gene Therapy Weekly, September 19th, 2002
At June 30, 2002, Avigen had $133 million in current assets, primarily cash equivalents and short-term investments, down $8 million from $141 million at March 31, 2002, the end of the previous quarter.
"Avigen continues to make progress towards the commercialization of an AAV vector based gene therapy," said John Monahan, PhD, president, and CEO. "During the last quarter we reported developments on many fronts including research advances, manufacturing improvements and the strengthening of our intellectual property...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.